Faculty, Staff and Student Publications
Publication Date
4-14-2020
Journal
Blood Cancer Journal
Abstract
Newly diagnosed AL amyloidosis patients were evaluated to develop a model for early assessment of treatment benefit at 6 months, integrating both hematologic (HR) and organ response (OR) assessment (testing cohort, Mayo: n = 473; validation cohort, Pavia: n = 575). Multiple OR were assessed as follows: All OR (AOR): response in all organs, mixed OR (MOR): response in some organs, no OR (NOR)]. AOR rates at 6 months improved with deepening HR; complete response (CR; 38%, 35%), very good partial response (VGPR; 30%, 26%), and partial response (PR; 16%, 21%), respectively. A composite HR/OR (CHOR) model was developed using incremental scoring based on hazard ratios with scores of 0-3 for HR (0-CR, 1-VGPR, 2-PR, 3-no response) and 0-2 for OR (0-AOR, 1-MOR, 2-NOR). Patients could be divided into two distinct CHOR groups (scores 0-3 and 4-5), with median OS in group 1 and group 2: Not reached vs. 34 months, p < 0.001 [Mayo] and 87 vs. 23 months, p < 0.001 [Pavia]. In conclusion, we developed a model that can assess multiple organs concurrently, and integrate both HR and OR assessments to determine early clinical benefit with treatment, which may be used as a surrogate end-point in trials and to compare outcomes with different therapies.
Keywords
Aged, Antineoplastic Agents, Cohort Studies, Combined Modality Therapy, Female, Hematologic Tests, Hematopoietic Stem Cell Transplantation, Humans, Immunoglobulin Light-chain Amyloidosis, Male, Middle Aged, Organ Dysfunction Scores, Remission Induction, Survival Rate, Treatment Outcome
Included in
Hematology Commons, Laboratory Medicine Commons, Medical Pathology Commons, Oncology Commons
Comments
Supplementary Materials
PMID: 32286270